Breo Ellipta: Phase III data

The double-blind, international Phase III SUMMIT trial in 16,485 COPD patients with moderate airflow limitation (50-70% predicted FEV1) and a history or risk of cardiovascular disease showed that once-daily 100/25 ug Breo Ellipta missed the primary endpoint of reducing

Read the full 391 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE